MarginsXMarginsX
Home › Markets › Health Care › IPHA

Innate Pharma S.A. ADS (IPHA)

IPHA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.41
-1.06% on the day
Market cap
$156.9M
Micro cap
Revenue · 2025
$10.0M
-55.2% on 2024
Net income · 2025
-$54.4M
-546.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1598599/000159859926000005/0001598599-26-000005-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerIPHA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryFrance
IPO year2019
SEC CIK0001598599
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inFrance

Financials · 2025

LineValue
Revenue$10.0M
Net income-$54.4M
Operating income-$59.7M
Net margin-546.1%
Operating margin-599.8%
Revenue growth-55.2%
Cash$31.0M
Total assets$69.3M
P/E (computed)Net income was not positive
P/S (computed)15.8×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
6.4 months
28.1M EUR cash at December 31, 2025
Share count, 1 year
+11.8%
2024-12-31 to 2025-12-31 · +17.8% over 3 years
Going-concern doubt
Yes
20-F filed April 1, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions and events raise material uncertainty (or raise substantial doubt as contemplated by PCAOB standards) on the Company's ability to continue as a going concern."
20-F 2026-04-01
Cash and burn28.1M EUR cash; operating cash flow -13.2M EUR a quarter.Report 2025-12-31
Shares outstanding93,719,323 (2025-12-31); 83,830,336 a year earlier; 79,542,627 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Associés, Le Bouscat, FrancePCAOB Form AP 2026-05-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
9.0M EUR-49.2M EUR-52.8M EUR28.1M EURNo debt tags9.0M EUR20-F 2026-04-01
FY 2024
2024-12-31
20.1M EUR-49.5M EUR-6.9M EUR66.4M EURNo debt tags20.1M EUR20-F 2026-04-01
FY 2023
2023-12-31
61.6M EUR-7.6M EUR-32.6M EUR70.6M EURNo debt tags61.6M EUR20-F 2026-04-01
FY 2022
2022-12-31
57.7M EUR-58.1M EUR-19.2M EUR84.2M EURNo debt tags57.7M EUR20-F 2025-04-30
FY 2021
2021-12-31
24.7M EUR-52.8M EUR-58.5M EUR103.8M EURNo debt tags24.7M EUR20-F 2024-04-04
FY 2020
2020-12-31
69.8M EUR-64.0M EUR-51.8M EUR136.8M EURNo debt tags69.8M EUR20-F 2023-04-06
FY 2019
2019-12-31
85.4M EUR-20.8M EUR34.9M EUR202.9M EURNo debt tags85.4M EUR20-F 2022-04-04
FY 2018
2018-12-31
94.0M EUR3.0M EUR-32.5M EUR152.3M EURNo debt tags94.0M EUR20-F 2021-04-27

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-02-06
Latest annual report20-F2026-04-01
Latest quarterly / interim6-K2026-11-12

Source: SEC EDGAR submissions feed, 340 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.2%
1 month-6.1%
3 months-45.6%
Year to date-21.1%
1 year-24.2%
From 52-week high-45.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
IVVDInvivyd Inc.$0.5377-7.63%$158.5M
STROSutro Biopharma Inc.$9.32-5.09%$154.7M
HUMAHumacyte Inc.$0.5403-3.24%$150.1M
TARAProtara Therapeutics Inc.$2.38-5.93%$146.5M
FATEFate Therapeutics Inc.$1.14-10.94%$138.6M
PALIPalisade Bio Inc.$1.03-8.04%$184.7M
CGENCompugen Ltd.$2.04-2.86%$193.0M
ENGNenGene Therapeutics Inc.$1.89-21.58%$126.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier